



Molecular Mechanisms and Treatment of Thymic Epithelial Tumors

Guest Editors:

Prof. Dr. Georgia Levidou

Department of Pathology,
Paracelsus Medical University,
90419 Nuremberg, Germany

**Prof. Dr. Stamatios E.
Theocharis**

First Department of Pathology,
Medical School, National and
Kapodistrian University of
Athens, Goudi, Athens, Greece

Deadline for manuscript
submissions:

closed (31 December 2024)

Message from the Guest Editors

Dear Colleagues,

Currently, early-stage thymic epithelial tumors are treated with surgical resection. For patients with advanced-stage or incomplete resected tumors, there is a necessity for adjuvant therapy, now consisting of platinum-based chemotherapy. The difficulties in TET treatment derive from their still largely unknown biology and pathogenetic mechanisms, and from the rarity of expert centers and lack of standardized treatments. A framework of expert multidisciplinary teams and of international networks is necessary in order to progress in our understanding and better deal with these rare tumors.

We hereby invite contributions to this Special Issue of *Biomedicines* describing novel molecular alterations underlying the pathobiology of TETs, possibly influencing epithelial cell growth and survival. In addition, manuscripts discussing developments in diagnostics or therapeutics for TET are also encouraged. We invite researchers and clinicians to submit original research articles and comprehensive review articles on the topic highlighted in this Special Issue of *Biomedicines*.

Dr. Georgia Levidou
Prof. Dr. Stamatios E. Theocharis
Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)